Tuesday, August 03, 2010 9:20:54 AM
http://ih.advfn.com/p.php?pid=nmona&article=43853092&symbol=CPHI
China Pharma Holdings, Inc. ("China Pharma") (NYSE Amex: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that it plans to release its second quarter 2010 financial results before the market opens on Tuesday, August 10, 2010.
The Company will hold a conference call at 8:00 am ET on August 10, 2010 to discuss second quarter 2010 results. Listeners may access the call by dialing 1-800-599-9816 or 1-617-847-8705 for international callers, access code: 52278171. A webcast will also be available through CPHI's website at http://www.chinapharmaholdings.com . A replay of the call will be accessible through August 17, 2010 by dialing 1-888-286-8010 or 1-617-801-6888 for international callers, access code: 49499602.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding distribution network across 30 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .
For more information, please contact:
China Pharma Holdings, Inc.
Phone: +86-898-6681-1730 (China)
Email: hps@chinapharmaholdings.com
CCG Investor Relations
Kalle Ahl, Account Manager
Phone: +1-646-833-3417(New York)
Email: kalle.ahl@ccgir.com
Vivian Chen, Sr. Market Intelligence Exec.
Phone: +1-646-701-7445(New York)
Email: vivian.chen@ccgir.com
SOURCE China Pharma Holdings, Inc.
Recent CPHI News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:05:47 PM
- China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split • PR Newswire (US) • 02/23/2024 09:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/15/2024 05:15:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:05:11 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:16:44 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/26/2024 10:04:49 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/12/2024 09:05:53 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/12/2024 07:42:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 09:05:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:05:21 PM
- China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device • PR Newswire (US) • 11/29/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:05:58 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/07/2023 09:05:29 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/27/2023 08:06:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/19/2023 08:06:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:05:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 07:40:13 PM
- China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs • PR Newswire (US) • 08/09/2023 12:30:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM